STOCKS

Adam Johnson

Founder,

BullseyeBrief.com

  • Founder of BullseyeBrief.com
  • Previous Host on Bloomberg TV
  • Graduate from Princeton

About Adam

Adam Johnson is the founder of BullseyeBrief.com, an investment letter which explores American Ingenuity through actionable stock picks. Previously he anchored several daily programs at Bloomberg TV, interviewing CEOs, heads of state, and prominent investors. Mr. Johnson also traded stocks, options, and oil at ING Asset Management, Louis Dreyfus, and Merrill Lynch. He graduated from Princeton with a BA in economics.

Adam's Articles

Covid has catapulted remote medical care from an experimental lifeline serving rural communities, to a mainstream methodology strengthening national hospital systems, observes Adam Johnson, growth stock expert and editor of Bullseye Brief.
I focus on a portfolio of dynamic, US companies propelling the world forward across multiple industries. Every pick shares three defining attributes: great story, compelling data, newsy catalyst, notes Adam Johnson, editor of Bullseye Brief.
Progenity (PROG) is a diagnostic testing company focused primarily on women’s health, explains Adam Johnson, growth stock expert and editor of Bullseye Brief.
Nine Meters Biopharma (NMTR) is a biotechnology company focusing on patients with gastrointestinal (GI) issues for which no treatments currently exist. The pipeline includes two drug candidates, one for Celiac disease and one for short bowel syndrome, suggests Adam Johnson, editor of Bullseye Brief.

Adam's Videos

SpaceX made history with the launch into orbit of the first manned space capsule by a private company. While we may not be vacationing in Mars any time soon, we are living in a world where technology is evolving faster than ever. In this panel discussion, get up to speed on the latest trends in the industry, explore breakthrough technologies, and hear about the most innovative disruptors reshaping the future.
Tune in to this 30-minute session to discuss several Med-Tech hybrid companies as case studies, explaining how they're redefining health and moving the world forward. Adam Johnson is long on all of them, and see's significant upside. "Health Care's Holy Grail" is his biggest investment theme for 2021, thanks to the convergence of wearables, AI, 5G, and telemedicine, and he's excited to share with you what he has learned!
Biotechnology offers significant upside if you know where to look. Adam Johnson, founder of BullseyeBrief.com, shares his three favorite biotech stocks under $3, why he's long and what he expects. These are some of the best examples of American Ingenuity!
Biotechnology offers significant upside if you know where to look. Adam Johnson, founder of BullseyeBrief.com, shares his three favorite biotech stocks under $3, why he's long and what he expects. These are some of the best examples of American Ingenuity!